Broadly neutralizing antibodies (bnAbs) have been considered to be potent therapeutic tools and potential vaccine candidates to enable protection against various clades of human immunodeficiency virus (HIV). The generation of bnAbs has been associated with enhanced exposure to antigen, high viral load and low CD4+ T cell counts, among other factors. However, only limited data are available on the generation of bnAbs in viraemic non-progressors that demonstrate moderate to high viraemia. Further, since HIV-1 subtype C viruses account for more than 50 % of global HIV infections, the identification of bnAbs with novel specificities is crucial to enable the development of potent tools to aid in HIV therapy and prevention. In the present study, we analysed and compared the neutralization potential of responses in 70 plasma samples isolated from ART-naïve HIV-1 subtype C-infected individuals with various disease progression profiles against a panel of 30 pseudoviruses. Among the seven samples that exhibited a neutralization breadth of ≥70 %, four were identified as ‘elite neutralizers’, and three of these were from viraemic non-progressors while the fourth was from a typical progressor. Analysis of the neutralization specificities revealed that none of the four elite neutralizers were reactive to epitopes in the membrane proximal external region (MPER), CD4-binding site and V1V2 or V3 glycan. However, two of the four elite neutralizers exhibited enhanced sensitivity towards viruses lacking N332 glycan, indicating high neutralization potency. Overall, our findings indicate that the identification of potent neutralization responses with distinct epitope specificities is possible from the as yet unexplored Indian population, which has a high prevalence of HIV-1 subtype C infection.
McGuireAT,
GlennJA,
LippyA,
StamatatosL.
Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol2014; 88:2645–2657 [View Article][PubMed]
GrayES,
MadigaMC,
HermanusT,
MoorePL,
WibmerCK et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol2011; 85:4828–4840 [View Article][PubMed]
LandaisE,
HuangX,
Havenar-DaughtonC,
MurrellB,
PriceMA et al. Broadly neutralizing antibody responses in a large longitudinal sub-saharan hiv primary infection cohort. PLoS Pathog2016; 12:e1005369[Crossref]
CohenK,
AltfeldM,
AlterG,
StamatatosL.
Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol2014; 88:13310–13321 [View Article][PubMed]
GaardboJC,
GerstoftJ,
NielsenSD.
Viremic nonprogressors. In
HopeTJ,
StevensonM,
RichmanD.
(editors) Encyclopedia of AIDS New York: Springer; 2015 pp. 1–9
AndrabiR,
ChoudharyAK,
BalaM,
KalraR,
PrakashSS et al. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence. Arch Virol2011; 156:1787–1794 [View Article][PubMed]
KhanL,
MakhdoomiMA,
KumarS,
NairA,
AndrabiR et al. Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. PLoS One2015; 10:e0125575 [View Article][PubMed]
PrakashSS,
AndrabiR,
KumarR,
LodhaR,
KabraSK et al. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India. Arch Virol2012; 157:1797–1801 [View Article][PubMed]
GooL,
ChohanV,
NduatiR,
OverbaughJ.
Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med2014; 20:655–658 [View Article][PubMed]
MuenchhoffM,
AdlandE,
KarimanziraO,
CrowtherC,
PaceM et al. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med2016; 8:358ra125 [View Article][PubMed]
De BoerRJ,
PerelsonAS.
How germinal centers evolve broadly neutralizing antibodies: the breadth of the follicular helper T cell response. J Virol2017; 91:e00983-17 [View Article][PubMed]
Doria-RoseNA,
KleinRM,
DanielsMG,
O'DellS,
NasonM et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol2010; 84:1631–1636 [View Article][PubMed]
EulerZ,
van GilsMJ,
BunnikEM,
PhungP,
SchweighardtB et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis2010; 201:1045–1053 [View Article][PubMed]
MoorePL,
WilliamsonC,
MorrisL.
Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol2015; 23:204–211 [View Article][PubMed]
LandaisE,
HuangX,
Havenar-DaughtonC,
MurrellB,
PriceMA et al. Broadly neutralizing antibody responses in a large longitudinal sub-saharan HIV primary infection cohort. PLoS Pathog2016; 12:e1005369 [View Article][PubMed]
ScharfL,
WestAP,
GaoH,
LeeT,
ScheidJF et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci USA2013; 110:6049–6054 [View Article][PubMed]
van GilsMJ,
van den KerkhofTL,
OzorowskiG,
CottrellCA,
SokD et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol2016; 2:16199 [View Article][PubMed]
JacobRA,
MoyoT,
SchomakerM,
AbrahamsF,
Grau PujolB et al. Anti-V3/Glycan and anti-MPER neutralizing antibodies, but not anti-V2/Glycan site antibodies, are strongly associated with greater anti-HIV-1 neutralization breadth and potency. J Virol2015; 89:5264–5275[Crossref]
ChenY,
ZhangJ,
HwangKK,
Bouton-VervilleH,
XiaSM et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol2013; 191:1260–1275 [View Article][PubMed]
WalkerLM,
PhogatSK,
Chan-HuiP-Y,
WagnerD,
PhungP et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science2009; 326:285–289[Crossref]
MoorePL,
ShewardD,
NonyaneM,
RanchobeN,
HermanusT et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol2013; 87:4882–4894[Crossref]
BrineyBS,
WillisJR,
CroweJE.
Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One2012; 7:e36750[Crossref]
MoorePL,
GormanJ,
Doria‐roseNA,
MorrisL.
Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies. Immunol Rev2017; 275:217–229[Crossref]
DavisKL,
GrayES,
MoorePL,
DeckerJM,
SalomonA et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology2009; 387:414–426[Crossref]
CortiD,
LangedijkJPM,
HinzA,
SeamanMS,
VanzettaF et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One2010; 5:e8805[Crossref]
TraversSA.
Conservation, compensation, and evolution of N-linked glycans in the HIV-1 group M subtypes and circulating recombinant forms. Isrn Aids2012; 2012:823605 [View Article][PubMed]
MoyoT,
FerreiraR-C,
DavidsR,
SondayZ,
MoorePL et al. Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. Virology2017; 501:12–24[Crossref]
SokD,
PauthnerM,
BrineyB,
LeeJH,
Saye-FranciscoKL et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity2016; 45:31–45[Crossref]
CheedarlaN,
PrecillaKL,
BabuH,
VijayanKKV,
AshokkumarM et al. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. Sci Rep2017; 7:srep46557[Crossref]
LandaisE,
HuangX,
Havenar-DaughtonC,
MurrellB,
PriceMA et al. Broadly neutralizing antibody responses in a large longitudinal sub-saharan HIV primary infection cohort. PLOS Pathog2016; 12:e1005369[Crossref]
SokD,
DooresKJ,
BrineyB,
LeKM,
Saye-FranciscoKL et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med2014; 6:236ra63 [View Article][PubMed]
AnthonyC,
YorkT,
BekkerV,
MattenD,
SelhorstP et al. Cooperation between strain-specific and broadly neutralizing responses limited viral escape and prolonged the exposure of the broadly neutralizing epitope. J Virol2017; 91:e00828-17 [View Article][PubMed]
CôrtesFH,
PassaesCPB,
BelloG,
TeixeiraSLM,
VorsatzC et al. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J Acquir Immune Defic Syndr2015; 68:377–385[Crossref]
HeigeleA,
CameriniD,
van’t WoutAB,
KirchhoffF.
Viremic long-term nonprogressive HIV-1 infection is not associated with abnormalities in known Nef functions. Retrovirology2014; 11:13[Crossref]
LongoNS,
SuttonMS,
ShiakolasAR,
GuenagaJ,
JarosinskiMC et al. Multiple antibody lineages in one donor target the glycan-V3 supersite of the HIV-1 envelope glycoprotein and display a preference for quaternary binding. J Virol2016; 90:10574–10586[Crossref]
BerginPJ,
LangatR,
Omosa-ManyonyiG,
FarahB,
OuattaraG et al. Assessment of anti-HIV-1 antibodies in oral and nasal compartments of volunteers from 3 different populations. J Acquir Immune Defic Syndr2016; 73:130–137[Crossref]